Oraya Therapeutics

An Exciting New Treatment Option

Please check this section frequently for updates on news announcements, industry events, and for our latest media resources.

Upcoming Events

Swiss Vitreoretinal Group
April 10, 2014  |   Zurich, Switzerland
Keynote speaker: D. Moshfeghi (USA)
Stereotactic Radiotherapy for Wet AMD, a New Treatment Option

Frankfurt Retina Meeting
May 15-16, 2014  |   Frankfurt, Germany

Royal College of Ophthalmologists Annual Congress 2014
May 20-22, 2014  |   Birmingham, United Kingdom
Retina Day, Keynote speaker: Professor Norbert Bornfeld (Germany)
Radiotherapy for AMD: Current Status

Latest Press Releases

Friday, November 15, 2013 | Oraya® Therapeutics, Inc. announced today that initial three-year safety follow-up data from its INTREPID study of Oraya Therapy™ stereotactic radiotherapy for the treatment of wet age-related macular degeneration (AMD) were presented for the first time today during the America Academy of Ophthalmology’s (AAO) annual meeting in New Orleans…More >

Tuesday, November 12, 2013 | Oraya Therapeutics, Inc. and OnCore Manufacturing LLC announced today the production of the first commercial unit in the United States of the IRay® Radiotherapy System for the treatment of wet age-related macular degeneration (AMD)…More >

Wednesday, September 25, 2013 | Oraya Therapeutics, Inc. announced today the two-year results of its INTREPID study of Oraya Therapy™ Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD)…More >

Wednesday, August 14, 2013 | Oraya Therapeutics, Inc. announced today that the Oraya Therapy™ Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD) is now available at Optegra Manchester Eye Hospital…More >

Thursday, April 18, 2013 | Oraya Therapeutics, Inc. today announced that results of its INTREPID study evaluating the safety and efficacy of Oraya Therapy™ Stereotactic Radiotherapy…More >

Thursday, April 4, 2013 | New Therapy for Wet AMD Introduced in Switzerland by Oraya® Therapeutics and EyeRAD…More >

Latest News

November 7, 2013 | San Francisco Business Times
East Bay connection: Oraya, OnCore partnership a lesson in medical manufacturing.

November 4, 2013 | MedCity News
Healthcare startup with noninvasive, one-time wet AMD treatments touts two years of success.

October 2013 | Retina Today
Intrepid Study Demonstrates 2-Year Safety, Efficacy of Oraya Therapy.

October 2, 2013 | eyewireTV Weekly
Two-year results of Oraya Therapeutics’ INTREPID study are presented, showing that radiation therapy for wet AMD is safe and effective.

September 25, 2013 | eyewireToday
Oraya Therapeutics INTREPID Study Demonstrates 2-year Safety and Effectiveness of Non-invasive Therapy for Wet AMD.

September 2013 | EUROTIMES Seminar Supplement 12th EURETINA Congress
Oraya Therapy – A Significant Advance in the Treatment of Wet AMD

September 30, 2013 | CHOICE
X-ray Aid For Eyes

September 30, 2013 | Readers Digest
This Won’t Hurt A Bit

June/July, 2013 | Vision Magazine, Issue 60
Radiotherapy breakthrough to treat wet AMD

Presented at 2012 AAO-APAO Joint Meeting
IRay Plus Anti-VEGF Treatment for Patients with Wet Age-Related Macular Degeneration: The INTREPID Trial of Stereotactic Radiotherapy for Choroidal Neovascularization in AMD
Peter K. Kaiser, MD View Video >

Back To Top

© 2014 All rights reserved to Oraya Therapeutics The IRay® Radiotherapy System is an investigational device and is not available for sale in the U.S.A. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.